INTRODUCTION {#sec1}
============

Extracorporeal membrane oxygenation (ECMO) is increasingly used as rescue therapy for severe cardiopulmonary failure ([@B2]). In veno-arterial (V-A) ECMO treatment, the native heart and lung work in parallel with the extracorporeal circuit and the assessment of native cardiac output \[i.e., blood flow through the lungs (Q̇~Lung~)\] is difficult. The ongoing unloading of the right ventricle even at low V-A ECMO blood flow (Q̇~ECMO~) makes assessment of cardiac function during V-A ECMO treatment challenging. Monitoring of the cardiac function and the evolution of native cardiac output during V-A ECMO treatment is not well standardized. Echocardiography is often used, but it requires specific knowledge ([@B1]) and routine echocardiographic parameters may not be useful in this context because of altered circulatory physiology and changing cardiac loading conditions ([@B12]). Monitoring of the evolution of native cardiac output based on simple, noninvasive, and readily available measurements would therefore be helpful in clinical practice, particularly during weaning, since early weaning success is associated with a favorable prognosis ([@B9]).

Gas exchange during V-A ECMO should reflect the combined effect of ventilation and perfusion of the native lung and those of the V-A ECMO circuit ([@B21]). We hypothesize that during V-A ECMO weaning the ratio between changes in CO~2~ elimination at the lung and the V-A ECMO (V̇[co]{.smallcaps}~2ECMO~ and V̇[co]{.smallcaps}~2Lung~) is the same as the ratio between changes in the respective flows (Q̇~ECMO~ and Q̇~Lung~). We tested this hypothesis in this preliminary, hypothesis-generating study by measuring the elimination of CO~2~ over the native lung and the V-A ECMO and the respective blood flows and compared the calculated flow changes with those directly measured from the pulmonary artery and V-A ECMO circuit.

METHODS {#sec2}
=======

 {#sec2-1}

### Animal care, surgery, and anesthesia. {#sec2-1-1}

This study was performed as a preliminary, independent substudy of a yet-unpublished project evaluating regional abdominal circulation during V-A ECMO and systemic inflammation, where measurements were done before the main study protocol was started. The study complied with the *Guide for the Care and Use of Laboratory Animals* (National Academy of Sciences, 1996) and Swiss National Guidelines and was approved, including an amendment for this substudy, by the Commission of Animal Experimentation of Canton Bern, Switzerland (BE119/17).

We studied a convenience sample of four animals (2 male and 2 female, 51.5 ± 1.3 kg) before the main study protocol was started. The pigs fasted for 12 h with free access to water. After anesthesia induction with intravenous midazolam and atropine and oral intubation, anesthesia was maintained with propofol and fentanyl, and the depth was controlled by repeatedly testing the response to nose pinch in additional to bispectral index target \< 60 (BIS Quatro; Covidien, Mansfield, MA). Additional injections of fentanyl (50 µg) or midazolam (5 mg) were given as needed. Muscle relaxation was induced with rocuronium (0.5 mg/kg). Mechanical ventilation \[volume control mode, positive end-expiratory pressure (PEEP) 5 cmH~2~O, fraction of inspired O~2~ (${\text{F}I}_{\text{O}_{\text{2}}}$) 0.3\] was initiated with a tidal volume (V[t]{.smallcaps}) of 7 mL/kg and a respiratory rate aiming at an end-tidal P[co]{.smallcaps}~2~ ($\text{P}ET_{\text{C}\text{O}_{2}}$) of 45 mmHg. A 5-Fr introducer sheath was placed in the right carotid artery for arterial blood pressure measurement and arterial blood gas sampling. Two three-lumen central venous lines were placed in the right and left jugular veins for right atrial pressure measurement and continuous administration of sedatives and vasopressors. V-A ECMO with right atrial-aortic cannulation and a left atrial vent (Maquet Cardiohelp, Quadrox MECC oxygenator, Rastatt, Germany; Medtronic cannula and vent, Minneapolis, MN) were installed via a sternotomy, and a bolus of 2,500 IE of unfractioned heparin was given. An appropriately sized ultrasonic flow probe was placed on the pulmonary artery (16- or 18-mm internal diameter, Transonic PAU series, Ithaca, NY). During surgery, fluid was supplemented with Ringer lactate at an initial rate of 5 mL·kg^−1^·min^−1^ and increased to 10 mL·kg^−1^·min^−1^. Any visible blood loss was replaced by hydroxyethyl starch (HES; 6% Voluven; Fresenius Kabi, Bad Homburg, Germany), and V-A ECMO pump speed was adjusted to achieve a mixed or central venous saturation \> 50%.

### Measurements and data recording. {#sec2-1-2}

Pulmonary blood flow, i.e., cardiac output (Q̇~Lung~) and V-A ECMO blood flow (Q̇~ECMO~), was measured on the pulmonary artery main trunk and arterial ECMO tubing (Transonic PAU series, Ithaca, NY). Pulmonary end-tidal P[co]{.smallcaps}~2~ ($\text{P}ET_{\text{C}\text{O}_{2\text{Lung}}}$) and P[co]{.smallcaps}~2~ at the membrane lung (peCO~2ECMO~) were measured with a sidestream capnograph (GE Medical, Module E-COVX with automated correction to BTPS conditions). The carbon dioxide production (V̇[co]{.smallcaps}~2~) was calculated individually for native and membrane lungs from the tidal P[co]{.smallcaps}~2~ tracing as described below. We recorded sweep gas flow (V̇~ECMO~) manually. Arterial blood gases were taken before and after the study period. Pulmonary ventilation (V̇~Lung~) was kept constant. In the first animal, ventilator settings were kept identical to those before V-A ECMO \[tidal volume (V[t]{.smallcaps}) 0.465 L, 12 breaths/min\], whereas in the subsequent animals V̇~Lung~ was reduced to 2 L/min (V[t]{.smallcaps} 0.25 L, 8 breaths/min) as V-A ECMO was started and kept constant thereafter. In all animals 5 cmH~2~O PEEP and volume control mode were used (Servo-i; Maquet, Solna, Sweden). The fraction of inspired oxygen was set at 0.30. Measurements were performed in healthy animals 30 min after surgery was completed. Eventually, the pigs were euthanized by injection of 40 mmol of potassium chloride, and V-A ECMO stopped in deep anesthesia. Data were recorded with LabVIEW (National Instruments Corp., Austin, TX) for off-line analysis with SOLEASY (ALEA Solutions, Zürich, Switzerland) and MATLAB R2019a (MathWorks, Natick, MA).

### Experimental protocol. {#sec2-1-3}

The experiment consisted of three phases with varying sweep gas-to-blood flow ratios (i.e., the V̇/Q̇ of the membrane lung) to determine how the sweep gas-blood flow relationship at the V-A ECMO influences extracorporeal CO~2~ elimination (V̇[co]{.smallcaps}~2ECMO~). First, we reduced Q̇~ECMO~ and V̇~ECMO~ in parallel (stable V̇/Q̇ = 1; "reduction of V̇&Q̇" phase, rV̇&Q̇~ECMO~). Then we lowered V̇~ECMO~ with a constant Q̇~ECMO~ (V̇/Q̇ toward shunt; "reduction of V̇" phase, rV̇~ECMO~). Finally, we tested a V-A ECMO weaning trial, where Q̇~ECMO~ was reduced but V̇~ECMO~ was kept constant (V̇/Q̇ toward dead space; "reduction of Q̇" phase, rQ̇~ECMO~).

Q̇~ECMO~ and V̇~ECMO~ were set at 4 L/min each at baseline and afterward reduced, depending on the respective phase, to 75%, 50%, and 25% of baseline with an interval of 1 min for each condition ([Fig. 1](#F0001){ref-type="fig"}). The left atrial vent was clamped during these procedures, and the stepwise reduction of blood flow was not supported by vasopressors or inotropes.

![Experimental protocol with stepwise reduction of veno-arterial extracorporeal membrane oxygenation (V-A ECMO) sweep gas flow (V̇~ECMO~) and/or blood flow (Q̇~ECMO~). *Steps 1--4* of each phase \[reduction of V̇(V), reduction of Q̇(Q), and reduction of both (VQ)\] indicated at *top*.](zh50062078540001){#F0001}

### Calculation of V̇[co]{.smallcaps}~2~ for V-A ECMO. {#sec2-1-4}

Expiratory concentration of CO~2~ at the V-A ECMO exhaust was calculated from the expiratory partial pressure of CO~2~ at the V-A ECMO exhaust and used to calculate V̇[co]{.smallcaps}~2~ ([@B16], [@B23]), using actual barometric pressures (on average 722 mmHg). The experiments were performed at 540 m above sea level.
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### Calculation of V̇[co]{.smallcaps}~2~ for the lung. {#sec2-1-5}

Mean pulmonary expired carbon dioxide ($\text{P}E_{\text{C}\text{O}_{2}}$) was calculated by averaging the end-tidal carbon dioxide ($\text{P}ET_{\text{C}\text{O}_{2}}$) curve over the respiratory cycle with correction for the inspiratory-to-expiratory (I:E) ratio:
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This was verified by integration of the expiratory P[co]{.smallcaps}~2~ curve, which delivers the same result.

We then calculate V̇[co]{.smallcaps}~2Lung~:
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### Blood flow calculations. {#sec2-1-6}

[Figure 2](#F0002){ref-type="fig"} depicts the situation during V-A ECMO schematically. We define the following relationships, whereby Q̇ is flow and Δ~v-a~CO~2~ is the inflow-outflow difference in blood CO~2~ content in a given segment (Δ~v-ao~CO~2~ is the difference between venous and aortal CO~2~ content, Δ~v-LA~CO~2~ is the difference between venous and left atrial CO~2~ content, and Δ~v-pm~CO~2~ is the difference between venous and postmembrane CO~2~ content):
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![Schematics for veno-arterial extracorporeal membrane oxygenation (V-A ECMO). Q̇~ECMO~, V-A ECMO blood flow; Q̇~Lung~, lung blood flow; RA, right atrium; V̇[co]{.smallcaps}~2ECMO~, elimination of CO~2~ (V̇[co]{.smallcaps}~2~) at V-A ECMO; V̇[co]{.smallcaps}~2Lung~, V̇[co]{.smallcaps}~2~ at lung; V̇[o]{.smallcaps}~2~, oxygen intake; c~v~CO2, mixed venous CO~2~ content; c~pm~CO~2~, post oxygenator CO~2~ content; c[la]{.smallcaps}CO~2~, left atrial CO~2~ content; c~ao~CO~2~, aortal CO~2~ content.](zh50062078540002){#F0002}

We then implement [*Eqs. 4*](#E4){ref-type="disp-formula"} and [*6*](#E6){ref-type="disp-formula"} into [*Eq. 5*](#E5){ref-type="disp-formula"}:
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We now solve [*Eq. 7*](#E7){ref-type="disp-formula"} for Q̇~Lung~:

Q

˙

t

o

t

a

l

×

Δ

a

o

−

v

C

O

2

=

Q

˙

L

u

n

g

×

Δ

v

−

L

A

C

O

2

\+

Q

˙

E

C

M

O

×

Δ

v

−

p

m

C

O

2

Q

˙

L

u

n

g

\+

Q

˙

E

C

M

O

×

Δ

a

o

−

v

C

O

2

=

Q

˙

L

u

n

g

×

Δ

v

−

L

A

C

O

2

\+

Q

˙

E

C

M

O

×

Δ

v

−

p

m

C

O

2

Q

˙

L

u

n

g

×

Δ

a

o

−

v

C

O

2

−

Δ

v

−

L

A

C

O

2

=

Q

˙

E

C

M

O

×

Δ

v

−

p

m

C

O

2

−

Δ

a

o

−

v

C

O

2

Q

˙

L

u

n

g

=

Q

˙

E

C

M

O

×

Δ

v

−

p

m

C

O

2

−

Δ

a

o

−

v

C

O

2

Δ

a

o

−

v

C

O

2

−

Δ

v

−

L

A

C

O

2

As we aim to calculate Q̇~Lung~ with expired gas phase measurements only rather than calculating blood gas content from multiple blood gas samples, we modify [*Eq. 8*](#E8){ref-type="disp-formula"} with the following assumptions. As carbon dioxide production and carbon dioxide elimination are mathematical opposites, we use the absolute value function, thus eliminating negative values:
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We now implement [*Eqs. 9*](#E9){ref-type="disp-formula"}*--*[*11*](#E11){ref-type="disp-formula"} into [*Eq. 8*](#E8){ref-type="disp-formula"}:

Q

˙

L

u

n

g

=

Q

˙

E

C

M

O

×

V

˙

C

O

2

E

C

M

O

−

V

˙

C

O

2

t

o

t

a

l

V

˙

C

O

2

t

o

t

a

l

−

V

˙

C

O

2

L

u

n

g

[*Equation 5*](#E5){ref-type="disp-formula"} simplifies [*Eq. 12*](#E12){ref-type="disp-formula"} to
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There is a fixed relationship of Q̇~Lung~ and Q̇~ECMO~ with the respective eliminated CO~2~. This expresses our hypothesis that the ratio between the differences in V̇[co]{.smallcaps}~2ECMO~ and V̇[co]{.smallcaps}~2Lung~ is the same as the ratio between the differences in the respective flows (Q̇~ECMO~ and Q̇~Lung~). In our experimental setup, we cannot expect to reach a steady state, as step changes were set at 1 min. Therefore, we calculate pulmonary blood flow using the differences in V̇[co]{.smallcaps}~2~ and Q̇~ECMO~ during V-A ECMO weaning rather than applying it to steady-state conditions.
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### Normalization of uneven V̇/Q̇ at the V-A ECMO. {#sec2-1-7}

During phase rV̇&Q̇~ECMO~ with a constant V̇/Q̇~ECMO~ of 1, we expect the relationship in [*Eq. 14*](#E14){ref-type="disp-formula"} to work. However, ∆V̇[co]{.smallcaps}~2ECMO~ is influenced by V̇~ECMO~ and Q̇~ECMO~. Q̇~ECMO~ determines the amount of CO~2~ transported toward the membrane lung, and V̇~ECMO~ determines the amount of CO~2~ eliminated over the membrane lung with a major impact on ∆V̇[co]{.smallcaps}~2ECMO~ ([@B10], [@B13], [@B17]). ∆V̇[co]{.smallcaps}~2ECMO~ therefore does not necessarily represent ∆Q̇~ECMO~, when V̇/Q̇~ECMO~ differs from 1. During phase rQ̇~ECMO~, V̇[co]{.smallcaps}~2~ may decouple from Q̇~ECMO~. Accordingly, the ratio ∆V̇[co]{.smallcaps}~2ECMO~/∆V̇[co]{.smallcaps}~2Lung~ is affected by V̇~ECMO~ despite unchanged blood flows.

To correct for uneven V̇/Q̇, we normalized ∆V̇[co]{.smallcaps}~2ECMO~ into a new variable, ∆V̇[co]{.smallcaps}~2ECMONorm~, only dependent on Q̇~ECMO~ and independent of V̇~ECMO~, with [*Eq. 15*](#E15){ref-type="disp-formula"}. The correction factor f is expressed in [*Eq. 16*](#E16){ref-type="disp-formula"}.
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A formal deduction of this normalization is found in the [[appendix]{.smallcaps}](#app1){ref-type="app"}.

### Statistical analysis. {#sec2-1-8}

For statistical, mathematical, and graphical analysis, we used MATLAB R2019a (MathWorks, Natick, MA), including an extension pack under a creative commons license for the creation of Bland--Altman plots ([@B15]). Data are presented either individually or as a range. Correlation coefficients were calculated with Pearson's square (*r*^2^). Agreement between methods (calculated and measured Q̇~Lung~) was assessed with Bland--Altman analysis.

RESULTS {#sec3}
=======

 {#sec3-1}

### Baseline. {#sec3-1-1}

At baseline V̇~ECMO~ and Q̇~ECMO~ of 4 L/min, V̇[co]{.smallcaps}~2ECMO~ was between 202 and 243 mL/min, whereas V̇[co]{.smallcaps}~2Lung~ was between 13 and 193 mL/min, corresponding to a measured Q̇~Lung~ of 10--964 mL/min and representing a normal V̇[co]{.smallcaps}~2~ production for swine ([@B6]) (*step 1* for V̇, Q̇, and V̇Q̇ in [Table 1](#T1){ref-type="table"}).

###### 

Individual data sets

                ECMO      Lung                                     
  --------- ------------ ------- ----- ----- ------- ------- ----- -------
             *Animal 1*                                            
  V̇                                                                
      *1*      4,000      4,105   214   217   5,600    964    189   3,572
      *2*      3,000      4,092   177   212   5,600    917    189   3,647
      *3*      2,000      4,049   135   209   5,600   1,125   195   3,778
      *4*      1,000      4,071   77    203   5,600    980    196   3,934
  Q̇                                                                
      *1*      4,000      4,113   226   229   5,600    920    197   3,529
      *2*      4,000      3,147   202   179   5,600   1,035   200   3,520
      *3*      4,000      2,058   173   128   5,600   1,458   215   3,463
      *4*      4,000      1,207   140   88    5,600   1,915   244   3,348
  V̇Q̇                                                               
      *1*      4,000      4,068   211   213   5,600    843    202   3,859
      *2*      3,000      3,231   168   174   5,600   1,157   199   3,686
      *3*      2,000      2,191   120   126   5,600   1,376   227   3,945
      *4*      1,000      1,178   66    73    5,600   1,550   242   3,932
             *Animal 2*                                            
  V̇                                                                
      *1*      4,000      4,013   222   223   1,800    389    52     935
      *2*      3,000      4,010   194   229   1,800    387    61    1,077
      *3*      2,000      3,982   150   229   1,800    370    66    1,141
      *4*      1,000      3,994   86    223   1,800    358    60    1,065
  Q̇                                                                
      *1*      4,000      4,079   259   261   1,800    105    64    1,006
      *2*      4,000      3,016   236   205   1,800    503    73    1,073
      *3*      4,000      1,995   205   150   1,800    968    72     966
      *4*      4,000      1,048   160   97    1,800   1,349   87     944
  V̇Q̇                                                               
      *1*      4,000      4,016   245   245   1,800    126    75    1,236
      *2*      3,000      3,008   195   195   1,800    560    76    1,170
      *3*      2,000      2,019   142   143   1,800    991    88    1,245
      *4*      1,000      1,094   67    71    1,800   1,472   105   1,626
             *Animal 3*                                            
  V̇                                                                
      *1*      4,000      4,062   263   266   1,800    10     14     217
      *2*      3,000      4,043   228   270   1,800    10     18     264
      *3*      2,000      4,025   177   274   1,800     5     19     283
      *4*      1,000      3,989   102   266   1,800     2     22     333
  Q̇                                                                
      *1*      4,000      4,031   287   288   1,800     4     23     324
      *2*      4,000      2,966   261   225   1,800     8     22     296
      *3*      4,000      1,994   228   167   1,800    328    42     502
      *4*       N/A        N/A    N/A   N/A    N/A     N/A    N/A    N/A
  V̇Q̇                                                               
      *1*      4,000      4,074   260   262   1,800     9     42     651
      *2*      3,000      3,008   211   211   1,800    36     37     529
      *3*      2,000      1,973   168   167   1,800    399    57     677
      *4*      1,000       641    79    64    1,800   1327    103   1,035
             *Animal 4*                                            
  V̇                                                                
      *1*      4,000      4,170   239   244   2,000    59     22     378
      *2*      3,000      4,216   197   240   2,000    72     30     528
      *3*      2,000      4,188   154   244   2,000    39     34     592
      *4*      1,000      4,186   89    241   2,000    21     32     561
  Q̇                                                                
      *1*      4,000      4,177   248   254   2,000     9     31     515
      *2*      4,000      3,031   225   195   2,000    294    36     556
      *3*      4,000      2,064   192   142   2,000    616    58     845
      *4*      4,000      1,060   149   91    2,000    909    68     801
  V̇Q̇                                                               
      *1*      4,000      4,031   231   232   2,000    14     49     848
      *2*      3,000      3,098   188   191   2,000    259    55     899
      *3*      2,000      2,108   138   142   2,000    602    65     964
      *4*      1,000      1,051   75    78    2,000    928    78    1,060

Values (in mL/min) are individual data for all animals at baseline \[*step 1* at reduction of ventilation (V̇), reduction of blood flow (Q̇), and reduction of both (V̇Q̇)\] and every step of blood flow reduction. Extracorporeal membrane oxygenation (ECMO) Q̇ and Lung Q̇ denote readings from the respective flow probes. CO~2~ elimination (V̇[co]{.smallcaps}~2~) values were calculated according to [*Eqs. 1*](#E1){ref-type="disp-formula"}*--*[*3*](#E3){ref-type="disp-formula"} in [methods]{.smallcaps} with the reported barometric pressure for each day (728, 726, 711, and 721 mmHg). Note that *1*) in *animal 1* ventilation is high because baseline settings at respirator were 5.6 L/min \[tidal volume (V[t]{.smallcaps}) 465 mL, frequency 12 times/min\] and that *2*) during reduction of Q̇ phase the cardiovascular system of *animal 3* did not support the ECMO reduction to 25% of baseline, and therefore no measurement is available (N/A). V̇[co]{.smallcaps}~2Norm~ refers to a calculated V̇[co]{.smallcaps}~2~ for a sweep gas-to-blood flow ratio normalized toward 1 (for details see [[appendix]{.smallcaps}](#app1){ref-type="app"}). Q̇~calc~, calculated lung Q̇.

### Measurements at the V-A ECMO. {#sec3-1-2}

Per protocol, Q̇~ECMO~ remained unchanged from baseline during phase rV̇~ECMO~ (98--100% of baseline or 3,989--4,186 mL/min) and was reduced to a quarter of baseline in phase rV̇&Q̇~ECMO~ (641--1,178 mL/min, 16--29% of baseline). In phase "rQ̇~ECMO~," Q̇~ECMO~ was reduced to approximately a quarter in all animals except *animal 3* because of hemodynamic instability (25.4--49.5% of baseline or 1,048--1,994 mL/min) ([Table 1](#T1){ref-type="table"}).

The normalization function was calculated by fitting our data points into [*Eq. 16*](#E16){ref-type="disp-formula"} and retrieving the constant *c* = 1.157 (*r*^2^ = 0.995, *P* \< 0.001). V̇[co]{.smallcaps}~2ECMONorm~ correlated highly with Q̇~ECMO~, and the normalization improved correlation significantly ([Fig. 3](#F0003){ref-type="fig"}, *A* and *B*, respectively). In phase rV̇~ECMO~, reducing V̇~ECMO~ without any change in Q̇~ECMO~, V̇[co]{.smallcaps}~2ECMONorm~ was 194--249 mL/min or 93.3--100.1% of baseline. Without normalization, V̇[co]{.smallcaps}~2ECMO~ decoupled from Q̇~ECMO~, with a decrease from 205--246 mL/min to 73--96 mL/min in this phase ([Table 1](#T1){ref-type="table"}, [Fig. 3*A*](#F0003){ref-type="fig"}). V̇[co]{.smallcaps}~2ECMO~ values for phase rV̇&Q̇~ECMO~ dropped to roughly a quarter of baseline (64--74 mL/min, 25--33% of baseline) in parallel with reduced Q̇~ECMO~. During phase rQ̇~ECMO~, V̇[co]{.smallcaps}~2ECMONorm~ was 84--156 mL/min or 38--58% of baseline.

![Effect of the normalization of the sweep gas flow-to-blood flow ratio on the veno-arterial extracorporeal membrane oxygenation (V-A ECMO). *A*: scatterplot for V-A ECMO blood flow (Q̇~ECMO~) vs. elimination of CO~2~ at V-A ECMO (V̇[co]{.smallcaps}~2ECMO~). Smallest points represent phase rV̇~ECMO~; medium-sized points represent phase rQ̇~ECMO~; large points represent phase rV̇&Q̇~ECMO~. No correlations reached significant levels (*P* \< 0.05). *B*: scatterplot for Q̇~ECMO~ vs. V̇[co]{.smallcaps}~2ECMO~ normalized to ventilation-to-perfusion ratio (V̇/Q̇) = 1 (V̇[co]{.smallcaps}~2ECMONorm~), all data points considered. Smallest points represent phase rV̇~ECMO~; medium-sized points represent phase rQ̇~ECMO~; large points represent phase rV̇&Q̇~ECMO~. In phase rQ̇~ECMO~, *animal 3* did not tolerate the last reduction in V-A ECMO flow.](zh50062078540003){#F0003}

### Measurements at the lung. {#sec3-1-3}

During unchanged Q̇~ECMO~ (phase rV̇~ECMO~), Q̇~Lung~ remained close to baseline (2--980 mL/min) and did not change much within one animal, and V̇[co]{.smallcaps}~2~ stayed constant, accordingly.

During reduction of Q̇~ECMO~ in phase rV̇&Q̇~ECMO~ and phase rQ̇~ECMO~, Q̇~Lung~ increased from its low baseline values to 928--1,550 mL/min, and 328--1,914 mL/min, respectively ([Table 1](#T1){ref-type="table"}). V̇[co]{.smallcaps}~2Lung~ followed the changes in Q̇~Lung~ to 74--232 mL/min (rise of 28--57 mL/min from baseline, with stepwise increases in every animal) for phase rV̇&Q̇~ECMO~ and 39--233 mL/min for phase rQ̇~ECMO~ (rise of 18--45 mL/min from baseline) and remained steady at full Q̇~ECMO~ (phase rV̇~ECMO~, 21--188 mL/min; change of 7--8 mL/min from baseline) ([Table 2](#T2){ref-type="table"}). Q̇~Lung~ and V̇[co]{.smallcaps}~2Lung~ showed a high correlation ([Fig. 4](#F0004){ref-type="fig"}).

###### 

Calculation of stepwise reductions

                      ECMO       Lung                                     
  --------------- ------------ -------- ------ ------ ----- ------- ----- ------
                   *Animal 1*                                             
  V̇                                                                       
      *1*→*2*        −1,000      −13     −37     −6     0     −47     0     −1
      *2*→*3*        −1,000      −43     −42     −2     0     208     7    122
      *3*→*4*        −1,000       22     −59     −7     0    −145     1     −2
      Summed up      −3,000      −34     −138   −15     0     16      7    119
  Q̇                                                                       
      *1*→*2*          0         −966    −24    −50     0     115     3     66
      *2*→*3*          0        −1,089   −29    −51     0     423    15    313
      *3*→*4*          0         −851    −32    −40     0     457    28    605
      Summed up        0        −2,906   −86    −142    0     995    47    984
  V̇Q̇                                                                      
      *1*→*2*        −1,000      −837    −43    −38     0     314    −3    −59
      *2*→*3*        −1,000     −1,040   −47    −48     0     219    28    612
      *3*→*4*        −1,000     −1,013   −54    −54     0     174    15    286
      Summed up      −3,000     −2,890   −144   −140    0     707    41    838
                   *Animal 2*                                             
  V̇                                                                       
      *1*→*2*        −1,000       −3     −27     6      0     −2      9     −5
      *2*→*3*        −1,000      −28     −42     1      0     −17     4    −189
      *3*→*4*        −1,000       12     −61     −6     0     −13    −6     12
      Summed up      −3,000      −19     −130    1      0     −32     7    −181
  Q̇                                                                       
      *1*→*2*          0        −1,063   −22    −56     0     398     9    160
      *2*→*3*          0        −1,021   −31    −55     0     465     0     −9
      *3*→*4*          0         −947    −44    −53     0     381    15    268
      Summed up        0        −3,031   −98    −164    0    1,244   23    419
  V̇Q̇                                                                      
      *1*→*2*        −1,000     −1,008   −50    −50     0     434     0     7
      *2*→*3*        −1,000      −989    −52    −52     0     431    12    236
      *3*→*4*        −1,000      −925    −75    −72     0     481    17    217
      Summed up      −3,000     −2,922   −177   −174    0    1,346   30    460
                   *Animal 3*                                             
  V̇                                                                       
      *1*→*2*        −1,000      −19     −36     4      0      0      3    −15
      *2*→*3*        −1,000      −18     −50     4      0     −5      2     −8
      *3*→*4*        −1,000      −36     −75     −8     0     −3      3     13
      Summed up      −3,000      −73     −161    0      0     −8      8     −9
  Q̇                                                                       
      *1*→*2*          0        −1,065   −25    −63     0      4     −1    −11
      *2*→*3*          0         −972    −33    −58     0     320    20    326
      *3*→*4*         N/A        N/A     N/A    N/A    N/A    N/A    N/A   N/A
      Summed up        0        −2,037   −59    −121    0     324    19    315
  V̇Q̇                                                                      
      *1*→*2*        −1,000     −1,066   −49    −51     0     27     −5    −99
      *2*→*3*        −1,000     −1,035   −43    −45     0     363    20    459
      *3*→*4*        −1,000     −1,332   −89    −103    0     928    45    588
      Summed up      −3,000     −3,433   −181   −199    0    1,318   61    948
                   *Animal 4*                                             
  V̇                                                                       
      *1*→*2*        −1,000       46     −42     −4     0     13      8    −84
      *2*→*3*        −1,000      −28     −43     4      0     −33     4    −31
      *3*→*4*        −1,000       −2     −65     −2     0     −18    −2     −2
      Summed up      −3,000       16     −150    −3     0     −38    10    −117
  Q̇                                                                       
      *1*→*2*          0        −1,146   −24    −59     0     285     4     88
      *2*→*3*          0         −967    −32    −53     0     322    22    410
      *3*→*4*          0        −1,004   −43    −52     0     293    10    196
      Summed up        0        −3,117   −99    −164    0     900    37    693
  V̇Q̇                                                                      
      *1*→*2*        −1,000      −933    −43    −40     0     245     7    158
      *2*→*3*        −1,000      −990    −50    −49     0     343    10    195
      *3*→*4*        −1,000     −1,057   −63    −65     0     326    13    213
      Summed up      −3,000     −2,980   −155   −154    0     914    29    565

Calculations of stepwise reductions \[reduction of ventilation (V̇), reduction of blood flow (Q̇), and reduction of both (V̇Q̇)\] for all lung and extracorporeal membrane oxygenation (ECMO) data. Values (in mL/min) are individual data for all animals for measurements performed at the lung. The summed up category refers to the cumulative change from *step 1* to *step 4*. Note that during reduction of Q̇ phase the cardiovascular system of *animal 3* did not support the ECMO reduction to 25% of baseline, and therefore no measurement is available (N/A). Q̇~calc~, calculated lung Q̇.

![Correlation between lung blood flow (Q̇~Lung~) and CO~2~ elimination at the lung (V̇[co]{.smallcaps}~2Lung~) absolute values: scatterplot for Q̇~Lung~ vs. V̇[co]{.smallcaps}~2Lung~, all data points considered. Smallest points represent phase rV̇~ECMO~; medium-sized points represent phase rQ̇~ECMO~; large points represent phase rV̇&Q̇~ECMO~. Note that in *animal 1* ventilation and thus V̇[co]{.smallcaps}~2Lung~ is high, because baseline settings at respirator were 5.6 L/min \[tidal volume (V[t]{.smallcaps}) 465 mL, 12 times/min\]. This was the first animal, and the ventilator settings were not adjusted from previous settings. In phase rQ̇~ECMO~, *animal 3* did not tolerate the last reduction in veno-arterial extracorporeal membrane oxygenation (V-A ECMO) flow.](zh50062078540004){#F0004}

### Calculation of Q̇~Lung~. {#sec3-1-4}

The calculation of pulmonary blood flow from absolute V̇[co]{.smallcaps}~2~ values is imprecise and leads to a consistent overestimation ([Table 1](#T1){ref-type="table"}). This overestimation increases with increasing V̇/Q̇ at the lung, which is shown in *animal 1*, where we had increased ventilation compared with the other animals. In phase rV̇~ECMO~, we observe no change in measured Q̇~Lung~ as well as calculated changes in Q̇~Lung~. When differences between the short stepwise flow reductions are considered ([Table 2](#T2){ref-type="table"}), correlations are reestablished ([Fig. 5*B*](#F0005){ref-type="fig"}) and the respective Bland--Altman plot ([Fig. 5*A*](#F0005){ref-type="fig"}) shows a small bias with acceptable limits of agreement. True blood flow changes are underestimated since bias is positive. Bias stays constant over the measured range (*R*^2^ = −0.16, *P* = 0.5). When phase rV̇~ECMO~ is excluded due to no expected change in blood flow, out of 23 blood flow change calculations, an opposite direction of the flow change is calculated in 4 instances. In all of these instances, the value of the change is below the least significant change, which is 113 mL/min. When the entire reduction steps are summarized ([Table 2](#T2){ref-type="table"} and [Fig. 5*C*](#F0005){ref-type="fig"}), the relationship becomes overt.

![*A*: Bland--Altman plot for all data points during veno-arterial extracorporeal membrane oxygenation (V-A ECMO) weaning. Bias is positive but close to zero, with wide limits of agreement. Bias stayed constant over increasing changes in lung blood flow (Q̇~Lung~) (*R*^2^ = 0.014). LoA, limits of agreement. *B*: scatterplot for the real change in Q̇~Lung~ vs. the calculated change in Q̇~Lung~ during V-A ECMO weaning. Smallest points represent phase rV̇~ECMO~; medium-sized points represent phase rQ̇~ECMO~; large points represent phase rV̇&Q̇~ECMO~. Linear regressions yield *animal 1*: *y* = 0.75 × *x* + 73.34; *animal 2*: *y* = 0.44 × *x* -- 47.85; *animal 3*: *y* = 0.73 × *x* + 7.17; *animal 4*: *y* = 0.8 × *x* -- 30.17. *C*: scatterplot for subsumed weaning steps for each animal. Linear regressions yield *animal 1*: *y* = 0.91 × *x* + 125.05; *animal 2*: *y* = 0.47 × *x* -- 166.98; *animal 3*: *y* = 0.70 × *x* + 34.8; *animal 4*: *y* = 0.79 × *x* -- 84.95.](zh50062078540005){#F0005}

DISCUSSION {#sec4}
==========

We show in a preliminary analysis that measurements of V̇[co]{.smallcaps}~2~ at both lung and V-A ECMO are possible with simple sidestream technology. Our model for the estimation of changes in Q̇~Lung~ predicts the directional change of pulmonary blood flow, i.e., cardiac output with acceptable accuracy in this small sample size ([@B3]). The measurements needed for our calculations (Q̇~ECMO~, V̇~ECMO~, V̇~Lung~, peCO~2ECMO~, $\text{P}ET_{\text{C}\text{O}_{2\text{L}\text{u}\text{n}\text{g}}}$) are easily performed with the use of standard sidestream capnographs, all of which are readily available in an ICU setting or an operating theater and require no specific training.

As expected from the ventilation-perfusion concept and the gas content equations in [Fig. 2](#F0002){ref-type="fig"} ([@B14]), we found that decrease in Q̇~ECMO~ and the consecutive increase in Q̇~Lung~ leads to a respective change in V̇[co]{.smallcaps}~2Lung~ and V̇[co]{.smallcaps}~2ECMONorm~. A closer look at [*Eq. 8*](#E8){ref-type="disp-formula"} as the background of our hypothesis shows an adaptation of the classic Berggren shunt equation ([@B11]). This seems intuitive, as the V-A ECMO is in concept an anatomical right-to-left shunt, where the ability to ventilate and oxygenate the shunted blood will clearly affect its functional influence ([Fig. 2](#F0002){ref-type="fig"}). Changing the sweep gas-to-blood flow ratio on the ECMO will vary the function of this anatomical shunt from true shunt (V̇~ECMO~ = 0 at any Q̇~ECMO~) to dead space (Q̇~ECMO~ = 0 at any V̇~ECMO~). V̇[co]{.smallcaps}~2ECMO~ only represents the shunt correctly as long as sweep gas/blood flow on the V-A ECMO are kept at a ratio of 1 (in phase rV̇&Q̇~ECMO~). For sweep gas-to-blood flow ratios differing from 1, sweep gas flow (V̇~ECMO~) will drastically change the amount of the eliminated CO~2~ ([@B10], [@B17]) independently of blood flow, a known phenomenon in states of shock or multiorgan failure ([@B13]). We could simulate this in the derivation of our normalization procedure (see [[appendix]{.smallcaps}](#app1){ref-type="app"}, [Figs. A2](#FA2){ref-type="fig"} and [A3](#FA3){ref-type="fig"}) and reproduce it in the experiment during the steps in phase rV̇~ECMO~ ([Table 1](#T1){ref-type="table"}).

The normalization of V̇[co]{.smallcaps}~2ECMO~ reestablishes a sweep gas-to-blood flow ratio of 1, and therefore restores the correlation between V̇[co]{.smallcaps}~2ECMONorm~ and Q̇~ECMO~. This newly calculated V̇[co]{.smallcaps}~2ECMONorm~ now is only dependent on blood flow and independent from ventilation and thus eliminates the influence of V̇/Q̇~ECMO~ mismatch on blood flow calculations. We used our data to calculate the constant *c* with a curve fitting function, in order to stay independent from blood gas measurements, although individual calculations would be possible from premembrane pH. We see the high goodness of fit of this normalization procedure as an indirect proof of the normalization function (see [[appendix]{.smallcaps}](#app1){ref-type="app"}, [Fig. A6](#FA6){ref-type="fig"}). During V-A ECMO weaning with a sweep gas-to-blood flow ratio of 1, it seems of little practical importance. Normalization might be particularly helpful to wean a low blood flow system with the primary intention to eliminate CO~2~, where the effect of increased ventilation is most relevant ([@B5]) (see [[appendix]{.smallcaps}](#app1){ref-type="app"}, [Fig. A3](#FA3){ref-type="fig"}). Whether this might be applicable to a veno-venous configuration would need to be investigated. In a veno-arterial configuration, normalization might allow accurate estimations of postmembrane CO~2~ pressures in blood, enabling a continuous gaseous oxygenator measurement to derive blood gas tensions (see [[appendix]{.smallcaps}](#app1){ref-type="app"}, [Fig. A2](#FA2){ref-type="fig"}).

A high V̇/Q̇~Lung~ will significantly increase the overall amount of CO~2~ eliminated and thus lead to an overestimation of pulmonary blood flow, whereas a reduction in V̇~ECMO~ will lead to a decrease in eliminated CO~2~ and thus to a rise in venous CO~2~ content. This in turn increases V̇[co]{.smallcaps}~2Lung~, to achieve a new steady state. However, as the V-A ECMO and the lung both drain venous blood from the right atrium, V̇[co]{.smallcaps}~2ECMO~ should increase simultaneously with the new steady state to fulfill [*Eq. 5*](#E5){ref-type="disp-formula"}. Our short measurement periods did preclude a steady state for CO~2~ elimination. Calculations of total blood flow for any given moment may therefore be impossible, because the lack of a steady state does not allow for sufficient accuracy. As we calculated Q̇~Lung~ through a deliberate step change in V̇[co]{.smallcaps}~2~, a steady state is not necessary, as there is no need for an absolute reference point. This also allows calculations for different settings of V̇~Lung~ (as shown with *animal 1*), as long as V̇~Lung~ remains constant.

The ratio of ventilation to perfusion in the lung will vary with hypoxic vasoconstriction, shunt, alveolar collapse, and dead space. Our V̇[co]{.smallcaps}~2Lung~, estimated from end-tidal P[co]{.smallcaps}~2~ in healthy lungs, showed an acceptable relationship with Q̇~Lung~, but stable minute ventilation on the lung was mandatory. As Q̇~Lung~ is the quantity to be calculated, a normalization procedure is not possible. As V̇[co]{.smallcaps}~2Lung~ can only represent blood flow that participates in gas exchange, shunt due to supine positioning of the animals could explain the bias of underestimation of changes in pulmonary blood flow with our method.

There are several possible limitations to our method: First, a V̇/Q̇~Lung~ mismatch (e.g., high shunt and/or high dead space) might result in a decrease of Q̇~Lung~-V̇[co]{.smallcaps}~2Lung~ correlation and might thus increase the bias significantly. Second, we did not document every V-A ECMO flow change with blood gas samples, because our aim was to calculate Q̇~Lung~ with gaseous measurements. Nevertheless, a meticulous documentation of blood gas status would strengthen our hypothesis and allow for alternative calculations of gas content and direct calculations of the normalization function. Third, V̇[co]{.smallcaps}~2~ was calculated with sidestream capnography, which is of limited accuracy. Signal shifts in the P[co]{.smallcaps}~2~-time tracing may introduce an error here. We did not rely on a breath-by-breath measurement, but averaged values over 1 min may help to minimize this possible influence. Mainstream calorimetric modules are available and used in assessing cardiac output, alveolar and dead space ventilation ([@B7], [@B18]--[@B20]). Mainstream capnography at the V-A ECMO gas outlet is feasible and may deliver accurate results for oxygen intake (V̇[o]{.smallcaps}~2~) and V̇[co]{.smallcaps}~2~ ([@B4], [@B22]). This might improve our results and overall accuracy compared with our calculations from sidestream end-tidal carbon dioxide. Fourth, this study was conducted in a small, clearly preliminary set of healthy animals and without any cardiovascular support.

The large scatter in pulmonary flow reflects the individual variability of native cardiac output during V-A ECMO treatment. In conclusion, we show that measurements of V̇[co]{.smallcaps}~2~ at the V-A ECMO are easily performed. A normalization procedure allows estimation of V̇[co]{.smallcaps}~2~ only dependent on blood flow without the influence of a V̇/Q̇ mismatch. This in turn lays the basis of blood flow calculations using V̇[co]{.smallcaps}~2~ values. Calculations of pulmonary blood flow using absolute values of carbon dioxide elimination are not possible in a nonsteady state with our method. The concept can be derived from basic physiological equations. Whether our method may result in a clinically useful approach and support V-A ECMO weaning, where assessment of cardiac output may help to evaluate weanability, has to be further evaluated. These preliminary findings need further confirmation in a larger study, also investigating low and high V̇/Q̇ states at the lung before exploring clinical applications.
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 {#sec8-1}

### Formal derivation of a normalized V̇[co]{.smallcaps}~2~ for a ventilation-to-perfusion ratio of 1. {#sec8-1-1}

As V̇[co]{.smallcaps}~2ECMO~ is dependent on the sweep gas flow ([@B17]), normalization of the V̇[co]{.smallcaps}~2~ at any given ventilation-to-perfusion ratio (V̇/Q̇) to a V̇/Q̇ of 1 (V̇[co]{.smallcaps}~2ECMONorm~) will render a variable dependent on blood flow (Q̇~ECMO~) only and independent from ventilation (V̇~ECMO~). This may facilitate the prediction of blood flow in the lung.

The theoretical deduction of this normalization is based on the description of V̇/Q̇ as ([@B8])$$\frac{\overset{˙}{\text{V}}}{\overset{˙}{\text{Q}}} = \text{σ}_{\text{C}\text{O}_{2}} \cdot \text{R} \cdot \text{T} \cdot \left( {1 + \text{Κ}_{c}} \right) \cdot \frac{\text{P}V_{CO_{2}} - \text{P}PM_{\text{C}\text{O}_{2}}}{\text{P}PM_{\text{C}\text{O}_{2}}}$$$\text{σ}_{\text{C}\text{O}_{2}}$is the solubility of CO~2~ in blood, *R* is the gas constant, and T is temperature. $\text{P}\text{v}_{\text{C}\text{O}_{2}}$ is venous CO~2~ partial pressure, and $\text{P}PM_{\text{C}\text{O}_{2}}$ is the postmembrane CO~2~ partial pressure. We assume that $\text{P}PM_{\text{C}\text{O}_{2}}$ is equal to PeCO~2ECMO~, which is measured at the V-A ECMO gas outlet. *K*~c~ indicates the equilibration constant of the CO~2~ + H~2~O ↔ $\text{HCO}_{3}^{-}$ + H^+^ reaction at a given pH. It describes the additional liberation of gaseous carbon dioxide from bicarbonate during the passage through the membrane lung. pK is the acid dissociation constant.
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Under the assumption of a constant pH, we can combine these individual constants into one overall constant *c*:
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For the derivation, we assume a constant venous carbon dioxide partial pressure and calculate gas fraction of expired CO~2~ (${\text{F}E}_{{CO}_{\text{2}}}$):
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We solve [*Eq. A1*](#EA1){ref-type="disp-formula"} for $\text{P}PM_{\text{C}\text{O}_{2}}$:
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A plot of this function shows the known hyperbolic dependence of alveolar, i.e. postmembrane, P[co]{.smallcaps}~2~ from ventilation (V̇ and Q̇ values are assumed from 0 to 4 with an interval of 0.25 L/min) ([Figs. A1](#FA1){ref-type="fig"} and [A2](#FA2){ref-type="fig"}).

The next step is to calculate V̇[co]{.smallcaps}~2ECMO~ and plot the function ([Fig. A3](#FA3){ref-type="fig"}). Note that the factor 1,000 is needed to convert the results in milliliters per minute.
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The diverging effects of the ventilation on the ECMO on P[co]{.smallcaps}~2~ and V̇[co]{.smallcaps}~2~ become apparent. In order to represent blood flow, we now normalize the given V̇[co]{.smallcaps}~2~ to a V̇/Q̇ of 1.

We define the correction factor f as the ratio of V̇[co]{.smallcaps}~2~ at V̇/Q̇ = 1 to the V̇[co]{.smallcaps}~2~ at any V̇/Q̇. We plot this correction factor f against V̇/Q̇:
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As V̇~V̇/Q̇ = 1~ is equal to Q̇, we can write
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This describes a hyperbolic dependence of f from V̇/Q̇ scaled with V̇/Q̇ and *c* ([Fig. A4](#FA4){ref-type="fig"}). Note that for a V̇/Q̇ of 1 the scaling and correction factor is 1.

Now, V̇[co]{.smallcaps}~2Norm~ can be calculated with [*Eqs. A3*](#EA3){ref-type="disp-formula"} and [*A5*](#EA5){ref-type="disp-formula"}. We plot this new function V̇[co]{.smallcaps}~2Norm~, which is independent of V̇ or V̇/Q̇ ([Fig. A5](#FA5){ref-type="fig"}):
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It is clear from this resolved [*Eq. A6*](#EA6){ref-type="disp-formula"} that V̇[co]{.smallcaps}~2Norm~ is dependent on Q̇ and $\text{P}\text{v}_{\text{C}\text{O}_{2}}$, as well as the constant *c*, which itself is dependent on temperature and pH.

It seems intuitive that [*Eq. A6*](#EA6){ref-type="disp-formula"} can simply be achieved by implementing V̇/Q̇ = 1 and substituting Q̇ for V̇ in [*Eq. A3*](#EA3){ref-type="disp-formula"}. This calculation eliminates the dependence of ventilation, and V̇[co]{.smallcaps}~2Norm~ will represent blood flow at any V̇/Q̇ (see [Fig. A5](#FA5){ref-type="fig"}).

This derivation assumes perfect conditions and depends on venous $\text{P}\text{v}_{\text{C}\text{O}_{2}}$ and pH, which are as a limitation of our study unknown. Therefore, the function has to be approximated from measured data, as described in the following section.

### Retrieving the normalization function from measured data. {#sec8-1-2}

We calculated the necessary correction factors using the measured data and [*Eq. A4*](#EA4){ref-type="disp-formula"}.

Then, the correction factors were plotted against V̇/Q̇ and the coefficient *c* was received ([Fig. A6](#FA6){ref-type="fig"}).
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It is a limitation of our study that our measurements of sweep gas flow (set and read by hand) are much more inaccurate than the blood flow readings. Additionally, instantaneous $\text{P}\text{v}_{\text{C}\text{O}_{2}}$ and pH measurements to calculate *c* are not available. Inexact ventilation measurements will introduce an error in the position of the normalization curve, where a small shift around a V̇/Q̇ of 1 will have a large impact on the slope of the function. Small errors in measurement of V̇[co]{.smallcaps}~2~, V̇, or Q̇ will therefore largely influence *c* ([Fig. A4](#FA4){ref-type="fig"}). However, the calculated function with empirically derived *c* shows almost perfect goodness of fit and the normalization of V̇[co]{.smallcaps}~2ECMO~ with this correction function shows very strong correlations between V̇[co]{.smallcaps}~2ECMONorm~ and Q̇~ECMO~ within the range of our measurements ([Fig. 3](#F0003){ref-type="fig"}, main text).

![Relationship between ventilation-to-perfusion ratio (V̇/Q̇) and postmembrane P[co]{.smallcaps}~2~ ($\text{P}PM_{CO_{2}}$). Colors refer to different V̇/Q̇ data points resulting from the chosen interval of 0.25.](zh5006207854a001){#FA1}

![Three-dimensional mesh plot showing postmembrane P[co]{.smallcaps}~2~ ($\text{P}PM_{CO_{2}}$, mmHg) as a function of ventilation (L/min) and blood flow (L/min).](zh5006207854a002){#FA2}

![Three-dimensional mesh plot showing elimination of CO~2~ at veno-arterial extracorporeal membrane oxygenation (V̇[co]{.smallcaps}~2ECMO~, mL/min) as a function of ventilation (L/min) and blood flow (L/min).](zh5006207854a003){#FA3}

![Correction factor f calculated as a function of ventilation-to-perfusion ratio (V̇/Q̇). Colors refer to different V̇/Q̇ data points resulting from the chosen interval of 0.25.](zh5006207854a004){#FA4}

![Three-dimensional mesh plot showing elimination of CO~2~ at veno-arterial extracorporeal membrane oxygenation (V̇[co]{.smallcaps}~2ECMO~, mL/min) normalized to ventilation-to-perfusion ratio = 1 as a function of ventilation (L/min) and blood flow (L/min). With normalization, the influence of ventilation on V̇[co]{.smallcaps}~2~ is eliminated.](zh5006207854a005){#FA5}

![Curve fitting for correction factor f as a function of ventilation-to-perfusion ratio (V̇/Q̇).](zh5006207854a006){#FA6}
